Altimmune, Inc.

Altimmune, Inc.verified

ALT

Price:

$7.47

Market Cap:

$529.59M

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryla...[Read more]

Industry

Biotechnology

IPO Date

2017-05-26

Stock Exchange

NASDAQ

Ticker

ALT

The PE Ratio as of April 2024 (TTM) for Altimmune, Inc. (ALT) is -4.50

According to Altimmune, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -4.50. This represents a change of 43.52% compared to the average of -3.14 of the last 4 quarters.

Altimmune, Inc. (ALT) Historical PE Ratio (quarterly & annually)

How has ALT PE Ratio performed in the past?

The mean historical PE Ratio of Altimmune, Inc. over the last ten years is -3.83. The current -4.50 PE Ratio has changed 11.65% with respect to the historical average. Over the past ten years (40 quarters), ALT's PE Ratio was at its highest in in the March 2015 quarter at 4.83. The PE Ratio was at its lowest in in the June 2014 quarter at -13.82.

Quarterly (TTM)
Annual

Average

-3.83

Median

-3.25

Minimum

-9.11

Maximum

0.16

Altimmune, Inc. (ALT) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Altimmune, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 720.26%

Maximum Annual PE Ratio = 0.16

Minimum Annual Increase = -446.74%

Minimum Annual PE Ratio = -9.11

Quarterly (TTM)
Annual
YearPE RatioChange
2023-6.77-25.68%
2022-9.11131.74%
2021-3.93-33.31%
2020-5.90387.76%
2019-1.21720.26%
2018-0.15-73.15%
2017-0.55-446.74%
20160.16-101.92%
2015-8.26221.78%
2014-2.5733.69%

Altimmune, Inc. (ALT) Average PE Ratio

How has ALT PE Ratio performed in the past?

The current PE Ratio of Altimmune, Inc. (ALT) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages

3-year avg

-6.61

5-year avg

-5.38

10-year avg

-3.83

Altimmune, Inc. (ALT) PE Ratio vs. Peers

How is ALT’s PE Ratio compared to its peers?

Altimmune, Inc.’s PE Ratio is less than Reviva Pharmaceuticals Holdings, Inc. (-1.97), less than Athira Pharma, Inc. (-0.69), less than Fortress Biotech, Inc. (-0.43), greater than ACADIA Pharmaceuticals Inc. (-45.69), greater than Cabaletta Bio, Inc. (-8.89), greater than Akero Therapeutics, Inc. (-7.76), less than Terns Pharmaceuticals, Inc. (-3.86), greater than Madrigal Pharmaceuticals, Inc. (-11.26), less than Inozyme Pharma, Inc. (-3.87), greater than Viking Therapeutics, Inc. (-75.30), greater than Anavex Life Sciences Corp. (-7.00), greater than Cassava Sciences, Inc. (-9.14), greater than INmune Bio, Inc. (-6.33), less than BioVie Inc. (-0.42), less than Cognition Therapeutics, Inc. (-2.49), greater than Ardelyx, Inc. (-22.89), less than Zura Bio Limited (-1.55), less than Hepion Pharmaceuticals, Inc. (-0.13), less than AVROBIO, Inc. (4.12), less than Verastem, Inc. (-3.09), less than X4 Pharmaceuticals, Inc. (-2.03), less than Galera Therapeutics, Inc. (-0.15), greater than Day One Biopharmaceuticals, Inc. (-7.38), less than HOOKIPA Pharma Inc. (-0.86),

Build a custom stock screener for Altimmune, Inc. (ALT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Altimmune, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Altimmune, Inc. (ALT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Altimmune, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Altimmune, Inc.'s PE Ratio?

How is the PE Ratio calculated for Altimmune, Inc. (ALT)?

What is the highest PE Ratio for Altimmune, Inc. (ALT)?

What is the 3-year average PE Ratio for Altimmune, Inc. (ALT)?

What is the 5-year average PE Ratio for Altimmune, Inc. (ALT)?

How does the current PE Ratio for Altimmune, Inc. (ALT) compare to its historical average?